Sarcoma and Solid Tumors

Solid tumors are masses that can grow almost anywhere in the body with the exception of the blog (hematological cancer). Solid tumors as split into two categories: sarcomas and carcinomas.

Our research team looks for ways to decrease the size and impact of solid tumors, or to slow the growth of the tumor in the safest way possible. This is determined through a combination of inhibitors, radiation treatments, and other therapies. Our researchers also evaluate tumors through biopsies to better understand what the genetic make-up of the tumor is and how it can be treated.

ALTE16C1, Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma

Protocol ID: ALTE16C1

Disease: Solid Tumors

Who can participate?: Male patients must be ≥ 18 and ≤ 50 years of age at the time of enrollment.

Lead Researcher: Mark A. Ranalli

Evaluation of ctDNA as prognostic biomarker for patients with newly diagnosed localized Ewing sarcoma or osteosarcoma

Protocol ID: ctDNA

Disease: Solid Tumor

Who can participate?: More than 12mo; histologic diagnosis of NEWLY diagnosed Ewing or osteosarcoma; no prior chemo or tumor resection.

Lead Researcher: Bhuvana A. Setty

MATCH - Phase 2 Sub protocol of Olaparib in patients with tumors harboring defects in DNA damage repair genes.

Protocol ID: APEC1621H

Disease: Solid Tumors 

Who can participate?: Prior enrollment on APEC1621SC
Ages >12 months and < 21 years of age
Must have Radiographically measurable disease
Enrollment after > 21 days after the last cytotoxic or myelosuppressive chemotherapy.

Lead Researcher: Mark A. Ranalli

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

Protocol ID: ARST1321

Disease: Solid tumors

Who can participate?: Patients must be ≥ 2 years at the time of the biopsy that established the diagnosis of NRSTS will be eligible. BSA> 0.5m2

Lead Researcher: Mark A. Ranalli, MD

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Protocol ID: ADVL1622

Disease: Refractory Sarcoma, Wilms & Other Rare Tumors

Who can participate?: Patients must be ≥ 2 and ≤ 30 years of age at the time of study entry for all strata except upper age limit of ≤ 18 years of age for MTC, RCC and HCC.

Lead Researcher: Mark A. Ranalli

Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and human Interferon beta in patients with refractory solid tumors

Protocol ID: Vyriad

Disease: Refractory Solid Tumors

Who can participate?: Patients must be > 365 days and < 31 years of age

Lead Researcher: Mark A. Ranalli, MD

MATCH- Phase 2 Subprotocol of Loxo-101 (Larotrectinib) in patients with tumors harboring actionable NTRK Fusions

Protocol ID: APEC1621A

Disease: Solid Tumors

Who can participate?: Patients must be greater than 12 months of age and less than 21 years of age at the time of study enrollment

Lead Researcher: Mark A. Ranalli, MD

MATCH-Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 Alterations

Protocol ID: APEC1621B

Disease: Solid tumors

Who can participate?: Be between 6 months and less than 18 years of age on day of signing informed consent/assent (NBL and Osteo closed)

Lead Researcher: Mark A. Ranalli, MD

MATCH- Phase 2 Sub Protocol of Tazemetostat in patients with tumors harboring alternation in EZh2 or members of SWI/SNF complex

Protocol ID: APEC1621C

Disease: Solid tumor

Who can participate?: Patients must be ≤ 21 years of age at the time of diagnosis

Lead Researcher: Mark A. Ranalli, MD

MATCH Phase 2 Sub Protocol of LY3023414 in Patients with Solid Tumors

Protocol ID: APEC1621D

Disease: Solid Tumors

Who can participate?: Ages > 2 - < 19 years

Lead Researcher: Mark A. Ranalli, MD

MATCH- Phase 2 Sub protocol of Selumetinib (AZD6244 Hydrogen Sulfate) in patients with tumors harboring activating MAPK pathway mutations

Protocol ID: APEC1621E

Disease: Solid Tumor

Who can participate?: No specific age requirement

Lead Researcher: Mark A. Ranalli, MD

MATCH- Phase 2 Sub Protocol of Ensartinib patients with tumors harboring ALK or ROS1 genomic alterations

Protocol ID: APEC1621F

Disease: Solid tumors

Who can participate?: No specific age requirement

Lead Researcher: Mark A. Ranalli, MD

MATCH- Phase 2 Sub protocol of Vemurafenib in patients with tumors harboring BRAF V600 Mutations

Protocol ID: APEC1621G

Disease: Solid tumor

Who can participate?: Patients must be < 30 years of age

Lead Researcher: Mark A. Ranalli, MD

MATCH- APEC Screening Protocol for Molecular Analysis for Therapy Choice

Protocol ID: APEC1621SC

Disease: Solid tumor

Who can participate?: < 12 months of age at diagnosis with INRG Stage L1 or < 18 months of age at diagnosis with INRG Stage L2 or Stage Ms neuroblastoma/ganglioneuroblastoma

Lead Researcher: Mark A. Ranalli, MD

Renal Tumors Classification, Biology, and Banking Study

Protocol ID: AREN03B2

Disease: REN

Who can participate?: Patients must be < 30 years old at the time of diagnosis

Lead Researcher: Mark A. Ranalli, MD

Investigation of Early Lymphocyte Recovery in Patients with Osteosarcoma

Protocol ID: Early Lymphocyte Recovery in Patients with Osteosarcoma

Disease: OST

Who can participate?: Patients ≥1 year and < 31 years of age at the time of relapse will be eligible

Lead Researcher: Nicholas D. Yeager, MD

NCH Solid Tumor Biology Study: Collection and Banking of Fresh Tumor and Serum Specimens for Research Purposes

Protocol ID: NCHB001

Disease: Solid tumors

Who can participate?: No specific age requirement

Lead Researcher: Bhuvana A. Setty, MD

A Phase II Study of Pazopanib (GW786034, NSC# 737754 in Children, Adolescents and Young Adults with Refractory Solid Tumors

Protocol ID: ADVL1322

Disease: Solid tumors

Who can participate?: Patients must be at least 1 year and less than or equal to 18 years of age at the time of study entry.

Lead Researcher: Mark A. Ranalli, MD